{
  "links": "https://www.ycombinator.com/companies/sequence-bio",
  "name": "Sequence Bio",
  "headline": "Discovering the true signals of disease to power life-changing drugs.",
  "batch": "S19",
  "description": "90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.",
  "activity_status": "Active",
  "website": "https://www.sequencebio.com/",
  "founded_date": 2013.0,
  "team_size": 52.0,
  "location": "St. John's, Canada",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:genomics; industry:therapeutics; industry:drug-discovery",
  "founders": [
    {
      "name": "Jeremy Grushcow",
      "description": "Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003).\n\nPreviously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic)\n\nBest dog dad ever; 7 out of 10 human dad.",
      "linkedin": "https://www.linkedin.com/in/jeremygrushcow/"
    },
    {
      "name": "Chris Gardner",
      "description": null,
      "linkedin": "https://www.linkedin.com/in/chriscgardner/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown=\"  * [Research](https://www.sequencebio.com/</research>)\\n  * [Press](https://www.sequencebio.com/</press>)\\n  * [Privacy](https://www.sequencebio.com/</privacy>)\\n  * [Careers](https://www.sequencebio.com/</careers>)\\n  * [Contact](https://www.sequencebio.com/</contact>)\\n\\n\\n[ ![](https://www.sequencebio.com/assets/images/sequence-logo-white-30602556.svg) ](https://www.sequencebio.com/</>)\\n[Research](https://www.sequencebio.com/</research>) [News](https://www.sequencebio.com/</press>) [Privacy](https://www.sequencebio.com/</privacy>) [Careers](https://www.sequencebio.com/</careers>) [Contact](https://www.sequencebio.com/</contact>)\\n[ ![](https://www.sequencebio.com/assets/images/sequence-logo-288c0c4f.svg) ](https://www.sequencebio.com/</>)\\n[Research](https://www.sequencebio.com/</research>) [News](https://www.sequencebio.com/</press>) [Privacy](https://www.sequencebio.com/</privacy>) [Careers](https://www.sequencebio.com/</careers>) [Contact](https://www.sequencebio.com/</contact>)\\n#  discovering the true signals of disease to power life-changing medicines \\n####  90% of drug candidates fail, delaying help for people in need. We’re on a mission to change that. \\n[ Learn More  ](https://www.sequencebio.com/<#why_nl>)\\n#####  FEATURED NEWS \\n[ ![](https://www.datocms-assets.com/6966/1737653290-tb-web-thumb.png) ](https://www.sequencebio.com/<press/release/tom-barber-chief-scientific-officer/>)\\n#### [Sequence Bio Appoints Dr. Tom Barber as Chief Scientific Officer](https://www.sequencebio.com/<press/release/tom-barber-chief-scientific-officer/>)\\nFebruary 5, 2025\\n[ ![](https://www.datocms-assets.com/6966/1733926336-mun-rsa-thumb.png) ](https://www.sequencebio.com/<press/release/memorial-university-research-collaboration/>)\\n#### [Sequence Bio and Memorial University collaborate to study the genetics of multiple sclerosis](https://www.sequencebio.com/<press/release/memorial-university-research-collaboration/>)\\nDecember 16, 2024\\n[ ![](https://www.datocms-assets.com/6966/1723047098-ms-thumb.png) ](https://www.sequencebio.com/<press/release/multiple-sclerosis-genetics-study/>)\\n#### [Sequence Bio launches genetics study of familial multiple sclerosis](https://www.sequencebio.com/<press/release/multiple-sclerosis-genetics-study/>)\\nSeptember 20, 2024\\n##### NEWFOUNDLAND AND LABRADOR\\n## there's nowhere quite like it\\nBetter target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes. The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.\\n![](https://www.sequencebio.com/assets/images/icon-isolated-2aa9fbec.svg)\\n####  founder effect: less biological variation enables more efficient identification of low frequency, high impact variants \\n![](https://www.sequencebio.com/assets/images/icon-electronic-records-5fe51a6b.svg)\\n####  complete health records: highly consistent phenotypic stratification to uncover new links between variants and disease \\n#####  RESEARCH & DEVELOPMENT \\n##  better medicines, faster \\nOur platform is where systems biology and data-driven computation meet to identify the true signals of disease. See how we’re working with leading pharma and biotech to shorten R&D timelines with custom discovery cohorts. \\npartner with sequence bio\\n#####  sequence bio \\n##  leadership \\nWe’re a committed team local and global experts united in our mission to help improve health outcomes with better medicines, faster. [We're hiring, join the team](https://www.sequencebio.com/</careers>)\\n[ ![](https://www.datocms-assets.com/6966/1618918801-lh-web-thumb.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/lynn-healey-7b0b561b/>)\\n#### Lynn Healey \\nChief Executive Officer\\n[ ![](https://www.datocms-assets.com/6966/1737652822-tb-web-thumb-team.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/tom-barber-b596aa7/>)\\n#### Tom Barber PhD\\nChief Scientific Officer\\n[ ![](https://www.datocms-assets.com/6966/1568292863-press-release-homepage-square-1260x1260-joy.png) ](https://www.sequencebio.com/<https:/www.sequencebio.com/press/release/joy-buckle-vp-policy-planning/>)\\n#### Joy Buckle MBA MSc\\nVP, Policy & Planning\\n[ ![](https://www.datocms-assets.com/6966/1574872933-chris-mcdonald.jpeg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/chrisgmcdonald1/>)\\n#### Chris McDonald \\nVP, strategy & market development\\n[ ![](https://www.datocms-assets.com/6966/1666893012-bb-thumb.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/bariballew/>)\\n#### Bari Ballew PhD\\nSenior Director, Data Science & Analytics\\n[ ![](https://www.datocms-assets.com/6966/1578056470-team-alain.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/alainodea/>)\\n#### Alain O'Dea \\nSenior Director, Security and Infrastructure\\n[ ![](https://www.datocms-assets.com/6966/1535129816-team-gerry.jpg) ](https://www.sequencebio.com/<https:/www.med.mun.ca/Medicine/Faculty/Mugford,-Gerry.aspx>)\\n#### Gerry Mugford PhD\\nDirector, research\\n[ ![](https://www.datocms-assets.com/6966/1621504927-diane-thumb.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/diane-power-679763142/>)\\n#### Diane Power \\nDirector, Research Coordination\\n[ ![](https://www.datocms-assets.com/6966/1657290527-blair-davis.png) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/blair-davis-05a724b1/>)\\n#### Blair Davis \\nDirector, Medical Partnerships\\n[ ![](https://www.datocms-assets.com/6966/1621452553-kendra-lane-chief-of-staff-copy.png) ](https://www.sequencebio.com/<>)\\n#### Kendra Lane \\nDirector, Organizational Effectiveness\\n[ ![](https://www.datocms-assets.com/6966/1535130230-team-dave.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/david-phillips-cpa-ca-72744340/>)\\n#### Dave Phillips \\ndirector, finance\\n#####  SCIENTIFIC ADVISORS \\n[ ![](https://www.sequencebio.com/assets/images/team/advisor-euan-16ab5bfb.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/euanashley>)\\n#### Dr. Euan Ashley \\nStanford medicine\\n[ ![](https://www.sequencebio.com/assets/images/team/advisor-pek-6fcefdab.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/pek-lum-409334b>)\\n#### Dr. Pek Lum \\nauransa inc.\\n[ ![](https://www.sequencebio.com/assets/images/team/advisor-tly-fdd5b85f.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/terry-lynn-young-8ba1238/>)\\n#### Dr. Terry-Lynn Young \\nMemorial University\\n#####  SEQUENCE BIO LEADERSHIP \\n##  board of directors \\n[ ![](https://www.datocms-assets.com/6966/1535132690-board-mark.png) ](https://www.sequencebio.com/<https:/ca.linkedin.com/in/mark-dobbin-754367b>)\\n#### Mark Dobbin \\nkillick capital\\n[ ![](https://www.datocms-assets.com/6966/1621503588-brendan-paddick-tumbnail.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/brendanpaddick/>)\\n#### Brendan Paddick \\ncolumbus capital\\n[ ![](https://www.datocms-assets.com/6966/1619081147-jp-bod.jpg) ](https://www.sequencebio.com/<>)\\n#### John Phillips \\nklister credit corp\\n[ ![](https://www.datocms-assets.com/6966/1618918801-lh-web-thumb.jpg) ](https://www.sequencebio.com/<https:/www.linkedin.com/in/lynn-healey-7b0b561b/>)\\n#### Lynn Healey \\nsequence bio\\n[ ![](https://www.datocms-assets.com/6966/1621448357-dcvc-web.png) ](https://www.sequencebio.com/<https:/dcvc.com>)\\n[ ![](https://www.datocms-assets.com/6966/1535378936-killick.png) ](https://www.sequencebio.com/<https:/www.killickcapital.com>)\\n[ ![](https://www.datocms-assets.com/6966/1535378986-klister.png) ](https://www.sequencebio.com/<http:/www.klister.ca>)\\n[ ![](https://www.datocms-assets.com/6966/1621461119-columbus-capital-logo.png) ](https://www.sequencebio.com/<>)\\n[ ![](https://www.datocms-assets.com/6966/1535379039-pelorus.png) ](https://www.sequencebio.com/<http:/www.pelorusventure.com>)\\n[ ![](https://www.datocms-assets.com/6966/1566933656-yc-logo-white.png) ](https://www.sequencebio.com/<http:/www.ycombinator.com>)\\n[ ![](https://www.sequencebio.com/assets/images/sequence-logo-white-30602556.svg) ](https://www.sequencebio.com/</>)\\nSequence Bio100 New Gower Street, Suite 370St. John's, NL, A1C 6K3 Canada+1.800.296.3481\\n© 2025 Sequence Bio, Inc. All Rights Reserved.\\n#### Site\\n  * [Research](https://www.sequencebio.com/</research>)\\n  * [News](https://www.sequencebio.com/</press>)\\n  * [Privacy](https://www.sequencebio.com/</privacy>)\\n  * [Careers](https://www.sequencebio.com/</careers>)\\n  * [Contact](https://www.sequencebio.com/</contact>)\\n\\n\\n#### Social\\n  * [Facebook](https://www.sequencebio.com/<https:/www.facebook.com/sequencebio>)\\n  * [Twitter](https://www.sequencebio.com/<https:/twitter.com/sequencebio>)\\n  * [Linkedin](https://www.sequencebio.com/<https:/www.linkedin.com/company/sequence-bioinformatics-inc->)\\n\\n\\n#### Keep in touch\\nThanks!\\n![](https://www.sequencebio.com/assets/images/close-3e29b69b.svg)\\n#####  JOIN OUR MAILING LIST \\n##  Stay up to date with Sequence Bio! \\nBy signing up for our mailing list, you are consenting to receive emails from us regarding our services. You may unsubscribe at any time. \\nThanks!\\n\" markdown_with_citations=\"  * Research⟨1⟩\\n  * Press⟨2⟩\\n  * Privacy⟨3⟩\\n  * Careers⟨4⟩\\n  * Contact⟨5⟩\\n\\n\\n ![⟨6⟩ ](https://www.sequencebio.com/</>)\\nResearch⟨1⟩ News⟨2⟩ Privacy⟨3⟩ Careers⟨4⟩ Contact⟨5⟩\\n ![⟨7⟩ ](https://www.sequencebio.com/</>)\\nResearch⟨1⟩ News⟨2⟩ Privacy⟨3⟩ Careers⟨4⟩ Contact⟨5⟩\\n#  discovering the true signals of disease to power life-changing medicines \\n####  90% of drug candidates fail, delaying help for people in need. We’re on a mission to change that. \\n Learn More  ⟨8⟩\\n#####  FEATURED NEWS \\n ![⟨9⟩ ](https://www.sequencebio.com/<press/release/tom-barber-chief-scientific-officer/>)\\n#### Sequence Bio Appoints Dr. Tom Barber as Chief Scientific Officer⟨10⟩\\nFebruary 5, 2025\\n ![⟨11⟩ ](https://www.sequencebio.com/<press/release/memorial-university-research-collaboration/>)\\n#### Sequence Bio and Memorial University collaborate to study the genetics of multiple sclerosis⟨12⟩\\nDecember 16, 2024\\n ![⟨13⟩ ](https://www.sequencebio.com/<press/release/multiple-sclerosis-genetics-study/>)\\n#### Sequence Bio launches genetics study of familial multiple sclerosis⟨14⟩\\nSeptember 20, 2024\\n##### NEWFOUNDLAND AND LABRADOR\\n## there's nowhere quite like it\\nBetter target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes. The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.\\n![](https://www.sequencebio.com/assets/images/icon-isolated-2aa9fbec.svg)\\n####  founder effect: less biological variation enables more efficient identification of low frequency, high impact variants \\n![](https://www.sequencebio.com/assets/images/icon-electronic-records-5fe51a6b.svg)\\n####  complete health records: highly consistent phenotypic stratification to uncover new links between variants and disease \\n#####  RESEARCH & DEVELOPMENT \\n##  better medicines, faster \\nOur platform is where systems biology and data-driven computation meet to identify the true signals of disease. See how we’re working with leading pharma and biotech to shorten R&D timelines with custom discovery cohorts. \\npartner with sequence bio\\n#####  sequence bio \\n##  leadership \\nWe’re a committed team local and global experts united in our mission to help improve health outcomes with better medicines, faster. We're hiring, join the team⟨4⟩\\n ![⟨15⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/lynn-healey-7b0b561b/>)\\n#### Lynn Healey \\nChief Executive Officer\\n ![⟨16⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/tom-barber-b596aa7/>)\\n#### Tom Barber PhD\\nChief Scientific Officer\\n ![⟨17⟩ ](https://www.sequencebio.com/<https:/www.sequencebio.com/press/release/joy-buckle-vp-policy-planning/>)\\n#### Joy Buckle MBA MSc\\nVP, Policy & Planning\\n ![⟨18⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/chrisgmcdonald1/>)\\n#### Chris McDonald \\nVP, strategy & market development\\n ![⟨19⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/bariballew/>)\\n#### Bari Ballew PhD\\nSenior Director, Data Science & Analytics\\n ![⟨20⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/alainodea/>)\\n#### Alain O'Dea \\nSenior Director, Security and Infrastructure\\n ![⟨21⟩ ](https://www.sequencebio.com/<https:/www.med.mun.ca/Medicine/Faculty/Mugford,-Gerry.aspx>)\\n#### Gerry Mugford PhD\\nDirector, research\\n ![⟨22⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/diane-power-679763142/>)\\n#### Diane Power \\nDirector, Research Coordination\\n ![⟨23⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/blair-davis-05a724b1/>)\\n#### Blair Davis \\nDirector, Medical Partnerships\\n ![⟨24⟩ ](https://www.sequencebio.com/<>)\\n#### Kendra Lane \\nDirector, Organizational Effectiveness\\n ![⟨25⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/david-phillips-cpa-ca-72744340/>)\\n#### Dave Phillips \\ndirector, finance\\n#####  SCIENTIFIC ADVISORS \\n ![⟨26⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/euanashley>)\\n#### Dr. Euan Ashley \\nStanford medicine\\n ![⟨27⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/pek-lum-409334b>)\\n#### Dr. Pek Lum \\nauransa inc.\\n ![⟨28⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/terry-lynn-young-8ba1238/>)\\n#### Dr. Terry-Lynn Young \\nMemorial University\\n#####  SEQUENCE BIO LEADERSHIP \\n##  board of directors \\n ![⟨29⟩ ](https://www.sequencebio.com/<https:/ca.linkedin.com/in/mark-dobbin-754367b>)\\n#### Mark Dobbin \\nkillick capital\\n ![⟨30⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/brendanpaddick/>)\\n#### Brendan Paddick \\ncolumbus capital\\n ![⟨31⟩ ](https://www.sequencebio.com/<>)\\n#### John Phillips \\nklister credit corp\\n ![⟨15⟩ ](https://www.sequencebio.com/<https:/www.linkedin.com/in/lynn-healey-7b0b561b/>)\\n#### Lynn Healey \\nsequence bio\\n ![⟨32⟩ ](https://www.sequencebio.com/<https:/dcvc.com>)\\n ![⟨33⟩ ](https://www.sequencebio.com/<https:/www.killickcapital.com>)\\n ![⟨34⟩ ](https://www.sequencebio.com/<http:/www.klister.ca>)\\n ![⟨35⟩ ](https://www.sequencebio.com/<>)\\n ![⟨36⟩ ](https://www.sequencebio.com/<http:/www.pelorusventure.com>)\\n ![⟨37⟩ ](https://www.sequencebio.com/<http:/www.ycombinator.com>)\\n ![⟨6⟩ ](https://www.sequencebio.com/</>)\\nSequence Bio100 New Gower Street, Suite 370St. John's, NL, A1C 6K3 Canada+1.800.296.3481\\n© 2025 Sequence Bio, Inc. All Rights Reserved.\\n#### Site\\n  * Research⟨1⟩\\n  * News⟨2⟩\\n  * Privacy⟨3⟩\\n  * Careers⟨4⟩\\n  * Contact⟨5⟩\\n\\n\\n#### Social\\n  * Facebook⟨38⟩\\n  * Twitter⟨39⟩\\n  * Linkedin⟨40⟩\\n\\n\\n#### Keep in touch\\nThanks!\\n![](https://www.sequencebio.com/assets/images/close-3e29b69b.svg)\\n#####  JOIN OUR MAILING LIST \\n##  Stay up to date with Sequence Bio! \\nBy signing up for our mailing list, you are consenting to receive emails from us regarding our services. You may unsubscribe at any time. \\nThanks!\\n\" references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://www.sequencebio.com/</research>: Research\\n⟨2⟩ https://www.sequencebio.com/</press>: Press\\n⟨3⟩ https://www.sequencebio.com/</privacy>: Privacy\\n⟨4⟩ https://www.sequencebio.com/</careers>: Careers\\n⟨5⟩ https://www.sequencebio.com/</contact>: Contact\\n⟨6⟩ https://www.sequencebio.com/assets/images/sequence-logo-white-30602556.svg:  ![\\n⟨7⟩ https://www.sequencebio.com/assets/images/sequence-logo-288c0c4f.svg:  ![\\n⟨8⟩ https://www.sequencebio.com/<#why_nl>:  Learn More  \\n⟨9⟩ https://www.datocms-assets.com/6966/1737653290-tb-web-thumb.png:  ![\\n⟨10⟩ https://www.sequencebio.com/<press/release/tom-barber-chief-scientific-officer/>: Sequence Bio Appoints Dr. Tom Barber as Chief Scientific Officer\\n⟨11⟩ https://www.datocms-assets.com/6966/1733926336-mun-rsa-thumb.png:  ![\\n⟨12⟩ https://www.sequencebio.com/<press/release/memorial-university-research-collaboration/>: Sequence Bio and Memorial University collaborate to study the genetics of multiple sclerosis\\n⟨13⟩ https://www.datocms-assets.com/6966/1723047098-ms-thumb.png:  ![\\n⟨14⟩ https://www.sequencebio.com/<press/release/multiple-sclerosis-genetics-study/>: Sequence Bio launches genetics study of familial multiple sclerosis\\n⟨15⟩ https://www.datocms-assets.com/6966/1618918801-lh-web-thumb.jpg:  ![\\n⟨16⟩ https://www.datocms-assets.com/6966/1737652822-tb-web-thumb-team.jpg:  ![\\n⟨17⟩ https://www.datocms-assets.com/6966/1568292863-press-release-homepage-square-1260x1260-joy.png:  ![\\n⟨18⟩ https://www.datocms-assets.com/6966/1574872933-chris-mcdonald.jpeg:  ![\\n⟨19⟩ https://www.datocms-assets.com/6966/1666893012-bb-thumb.jpg:  ![\\n⟨20⟩ https://www.datocms-assets.com/6966/1578056470-team-alain.jpg:  ![\\n⟨21⟩ https://www.datocms-assets.com/6966/1535129816-team-gerry.jpg:  ![\\n⟨22⟩ https://www.datocms-assets.com/6966/1621504927-diane-thumb.jpg:  ![\\n⟨23⟩ https://www.datocms-assets.com/6966/1657290527-blair-davis.png:  ![\\n⟨24⟩ https://www.datocms-assets.com/6966/1621452553-kendra-lane-chief-of-staff-copy.png:  ![\\n⟨25⟩ https://www.datocms-assets.com/6966/1535130230-team-dave.jpg:  ![\\n⟨26⟩ https://www.sequencebio.com/assets/images/team/advisor-euan-16ab5bfb.jpg:  ![\\n⟨27⟩ https://www.sequencebio.com/assets/images/team/advisor-pek-6fcefdab.jpg:  ![\\n⟨28⟩ https://www.sequencebio.com/assets/images/team/advisor-tly-fdd5b85f.jpg:  ![\\n⟨29⟩ https://www.datocms-assets.com/6966/1535132690-board-mark.png:  ![\\n⟨30⟩ https://www.datocms-assets.com/6966/1621503588-brendan-paddick-tumbnail.jpg:  ![\\n⟨31⟩ https://www.datocms-assets.com/6966/1619081147-jp-bod.jpg:  ![\\n⟨32⟩ https://www.datocms-assets.com/6966/1621448357-dcvc-web.png:  ![\\n⟨33⟩ https://www.datocms-assets.com/6966/1535378936-killick.png:  ![\\n⟨34⟩ https://www.datocms-assets.com/6966/1535378986-klister.png:  ![\\n⟨35⟩ https://www.datocms-assets.com/6966/1621461119-columbus-capital-logo.png:  ![\\n⟨36⟩ https://www.datocms-assets.com/6966/1535379039-pelorus.png:  ![\\n⟨37⟩ https://www.datocms-assets.com/6966/1566933656-yc-logo-white.png:  ![\\n⟨38⟩ https://www.sequencebio.com/<https:/www.facebook.com/sequencebio>: Facebook\\n⟨39⟩ https://www.sequencebio.com/<https:/twitter.com/sequencebio>: Twitter\\n⟨40⟩ https://www.sequencebio.com/<https:/www.linkedin.com/company/sequence-bioinformatics-inc->: Linkedin\\n' fit_markdown='' fit_html=''",
  "generated_description": "Sequence Bio is a biotech company headquartered in St. John's, Newfoundland and Labrador, Canada. Founded in 2013, they emerged from Y Combinator's Batch S19 with a mission to revolutionize drug discovery. Their goal? To tackle the staggering statistic that 90% of drug candidates fail, leading to delays in delivering lifesaving treatments to those in need. By focusing on better drug target discovery informed by the unique genetic landscape of Newfoundland, they’re redefining the way we approach therapeutics.\n\nThe company boasts a team of 52 dedicated professionals, all united under the vision of transforming disease signals into actionable insights for drug development. With a focus on genomics, therapeutics, and drug discovery, Sequence Bio uses an integrated approach combining multi-omics data, real-world patient information, and well-characterized health records. This methodology allows them to identify low-frequency, high-impact genetic variants much more efficiently than traditional methods can.\n\nIn recent developments, they’ve made headlines by appointing Dr. Tom Barber as their Chief Scientific Officer and collaborating with Memorial University on studying the genetics of multiple sclerosis. Such collaborations underscore their commitment to leveraging local insights for global health advancements.\n\nTheir leadership team includes experts in various fields, from data science to policy planning, ensuring a robust framework to support their ambitious goals in research and development. They emphasize a commitment not just to scientific excellence, but to improving health outcomes faster through custom discovery cohorts, working closely with leading pharmaceutical and biotech firms.\n\nFor anyone intrigued by the blend of innovation in genomics and practical therapeutic applications, Sequence Bio is a company to watch. They’re not just another biotech firm; they’re positioning themselves as catalysts for change in a field where the stakes are literally life and death. \n\nIf you're keen to learn more, check out their website at [Sequence Bio](https://www.sequencebio.com/) for the latest on their research, press releases, and career opportunities."
}